more bad news from macbank, page-16

Hi Jimmy357

The Morningstar review on the 04/03/2014 has ACR rated as a HOLD. They have revised fair value down from $4.20 to $2.50. This is attributed to slower than expected sales in the US.

They also have a patent for their application of drugs through the skin until 2027 and another three drugs coming through the FDA system.

Current prices may be short-term aberration.
For my mind, the entity structure is a major benefit too. You don't have to pay CGT or tax on dividends earned.

At the current price, based on Morningstar research of $0.225 of earnings in 2014, they are looking at 13.15% return on earnings with a $1.71 share price. Dividends are smaller with a 4.3% forecast return ($0.074 for 2014).

If Morningstar's EPS figures are correct, then we are looking at Earnings return of 21.4% on todays share price in 2015.

Best of Luck
Lost